Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 3.9% – Time to Sell?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) traded down 3.9% during mid-day trading on Wednesday . The company traded as low as $26.3653 and last traded at $26.88. 150,058 shares were traded during mid-day trading, an increase of 199% from the average session volume of 50,104 shares. The stock had previously closed at $27.98.

Neoleukin Therapeutics Trading Down 3.9%

The stock has a market cap of $252.62 million, a price-to-earnings ratio of -8.64 and a beta of 1.11. The stock’s 50-day moving average price is $24.40 and its 200-day moving average price is $21.99.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.

The company’s lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.